公司概覽
業務類別 Biotechnology
業務概覽 MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Companyis currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
公司地址 1 Casper Street, Danbury, CT, USA, 06810
電話號碼 +1 818 661-5000
傳真號碼 --
公司網頁 https://www.mannkindcorp.com
員工數量 592
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. David B. Thomson, J.D.,PhD Executive Vice President, General Counsel and Secretary 美元 520.75K 07/04/2026
Dr. Stuart A. Tross, PhD Executive Vice President, Human Resources 美元 438.71K 07/04/2026
Mr. Michael E. Castagna, Pharm.D. Director and Chief Executive Officer 美元 789.44K 07/04/2026
Mr. Christopher B. Prentiss Chief Financial Officer and Principal Accounting Officer 美元 470.09K 07/04/2026
Mr. Dominic Marasco President, Endocrine Business Unit 美元 447.60K 07/04/2026
Dr. Ajay Ahuja, M.B.A.,M.D. Executive Vice President and Chief Medical Officer -- 07/04/2026
Mr. Sanjay R. Singh, M.B.A. Executive Vice President, Technical Operations -- 07/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Anthony C. Hooper Independent Director 07/04/2026
Dr. Michael A. Friedman M.D. Independent Director 07/04/2026
Mr. Ronald J. Consiglio Independent Director 07/04/2026
Dr. James S. Shannon, M.D.,M.R.C.P. Chairman of the Board 07/04/2026
Mr. Michael E. Castagna, Pharm.D. Director and Chief Executive Officer 07/04/2026
Mr. Steven B. Binder Director 07/04/2026
Ms. Christine A. Mundkur Independent Director 07/04/2026
Ms. Jennifer Grancio Independent Director 07/04/2026
Dr. Sabrina Kay, PhD Independent Director 07/04/2026
 
所屬ETF (更新日期: 02/05/2026 03:09)
代號 名稱 佔比% 持有日期
UWMProShares Ultra Russell20000.004%29/04/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.004%29/04/2026
TILTFlexShares Mstar US Mkt Factors Tilt ETF0.003%29/04/2026
QSMLWisdomTree U.S. Small Cap Quality Gr0.001%28/04/2026
PBSMInvesco PureBeta MSCI USA Small Cap ETF0.0004%31/05/2023
AVUQAvantis U.S. Quality ETF0.0004%29/04/2026
HDGProShares Hedge Replication0.0001%29/04/2026
RESMColumbia Research Enhanced Small Cap ETF0.0001%29/04/2026
RBProshares Russell 2000 Dynamic BufferETF0.00003%29/04/2026
AIEQAmplify AI Powered Equity ETF<0.000001%05/03/2026
DXUVDimensional US Vector Equity ETF<0.000001%04/03/2026
FADFirst Trust Multi Cap Gr AlphaDEX® ETF<0.000001%08/04/2026
FSCCFederated Hermes MDT Small Cap Core ETF<0.000001%01/08/2025
FSMDFidelity Small-Mid Multifactor ETF<0.000001%15/08/2025
FYCFirst Trust Small Cap Gr AlphaDEX® ETF<0.000001%08/04/2026
FYXFirst Trust Small Cap Core AlphaDEX® ETF<0.000001%08/04/2026
HKNDHumankind US Stock ETF<0.000001%24/11/2025
ISCViShares Morningstar Small-Cap Value ETF<0.000001%19/12/2025
IWCiShares Micro-Cap ETF<0.000001%02/03/2026
IWNiShares Russell 2000 Value ETF<0.000001%06/03/2026
  1    2   3    4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.